SHP-1 inhibitors and activators of t cells
By administering SHP-1-deficient immune cells and inhibitors, combined with lymphocyte activators, the TME is reprogrammed to enhance T-cell activation, addressing the limitations of current TME immunosuppression and achieving significant anti-tumor efficacy.
WO2025188921A1 Publication Date: 2025-09-11MDX MANAGEMENT LLC
53 Cites 0 Cited by
Patent Information
- Application Number
- PCT/US2025/018611
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-03-06
- Filing Date
- 2025-03-05
- Publication Date
- 2025-09-11
AI Technical Summary
Technical Problem
Current therapeutic approaches targeting individual inhibitory receptors (iRs) in the tumor microenvironment (TME) show weak-to-partial efficacy in controlling solid tumors, as they do not effectively inhibit the multi-pathway regulation mediated by SHP-1, leading to T-cell exhaustion and immunosuppression.
Method used
Administering immune cells deficient in SHP-1 expression or activity, combined with agents that inhibit SHP-1 signaling and lymphocyte activating agents, to reprogram the tumor microenvironment and enhance T-cell activation.
Benefits of technology
This approach dramatically bolsters anti-cancer immunity by rewiring immunosuppression, effectively reducing tumor burden and preventing therapeutic-induced toxicity.
✦ Generated by Eureka AI based on patent content.
Abstract
The present application provides a method of treating a cancer in an individual that involves administering to the individual a lymphocyte activating agent (e.g., a T cell activating agent) and an agent that inhibits SHP-1 signaling (e.g., TPI-1, PTP-1). In some cases, the method optionally further involves administering a TNFα inhibitor and / or a pro-inflammatory agent (such as TLR or STING agonists).
Need to check novelty before this filing date? Find Prior Art